Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 7/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.59 |
| ▸ | PRCP | P42785 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10236958 | 0.96 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL883275 | 0.96 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL13635819 | 0.96 | CYP3A4 (0.71) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL19521589 | 0.92 | CYP3A4 (0.65) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL204761 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL15586557 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2707003 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL204522 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL18463098 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 | |
| SCHEMBL2710862 | 0.91 | CYP3A4 (0.64) | CYP3A4CYP2C9KCNH2NR1I2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9932326-B2 | Potent and selective inhibitors of hepatitis C virus | Cocrystal Pharma, LLC (US) | 2018-04-03 | — | — | US | disclosed |
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| EP-2963034-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS Pharma, LLC. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-9181227-B2 | Potent and selective inhibitors of hepatitis C virus | COCRYSTAL PHARMA, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140350016-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY | 2014-11-27 | — | — | US | disclosed |
| US-8859595-B2 | Potent and selective inhibitors of hepatitis C virus | RFS PHARMA, LLC (US) | 2014-10-14 | — | — | US | disclosed |
| US-20130210774-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | EMORY UNIVERSITY (US) | 2013-08-15 | — | — | US | disclosed |
| WO-2012027712-A2 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | RFS PHARMA, LLC (US) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068518-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | CYP3A4 208/4885CYP2C9 329/4885KCNH2 4337/4885 |
| US-20130210774-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | CYP3A4 208/4885CYP2C9 329/4885KCNH2 4337/4885 |
| US-20140350016-A1 | POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, SLC10A1, PYGL | CYP3A4 208/4885CYP2C9 329/4885KCNH2 4337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.